Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study

International Journal of Stroke

Volumn 11, Issue 5, 2016, Pages 565-574

  Arihiro, Shoji ^a   Todo, Kenichi ^b   Koga, Masatoshi ^a   Furui, Eisuke ^c   Kinoshita, Naoto ^a   Kimura, Kazumi ^d   Yamagami, Hiroshi ^a   Terasaki, Tadashi ^e   Yoshimura, Sohei ^a   Shiokawa, Yoshiaki ^f   Kamiyama, Kenji ^g   Takizawa, Shunya ^h   Okuda, Satoshi ⁱ   Okada, Yasushi ^j   Nagakane, Yoshinari ^k   Kameda, Tomoaki ^l   Hasegawa, Yasuhiro ^m   Shibuya, Satoshi ⁿ   Ito, Yasuhiro ^o   Nakashima, Takahiro ^p   Takamatsu, Kazuhiro ^q   Nishiyama, Kazutoshi ^r   Matsuki, Takayuki ^a   Homma, Kazunari ^a   Takasugi, Junji ^b   Tokunaga, Keisuke ^a   Sato, Shoichiro ^a   Kario, Kazuomi ^l   Kitazono, Takanari ^s   Toyoda, Kazunori ^a   more..

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^b KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

^c KOHNAN HOSPITAL   (Japan)

^d KAWASAKI MEDICAL SCHOOL   (Japan)

^e JAPANESE RED CROSS KUMAMOTO HOSPITAL   (Japan)

^f KYORIN UNIVERSITY   (Japan)

^g Nakamura Memorial Hospital   (Japan)

^h TOKAI UNIVERSITY   (Japan)

ⁱ NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^j NATIONAL HOSPITAL ORGANIZATION KYUSHU MEDICAL CENTER   (Japan)

^k KYOTO SECOND RED CROSS HOSPITAL   (Japan)

^l JICHI MEDICAL UNIVERSITY   (Japan)

^m ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁿ South Miyagi Medical Center   (Japan)

^o TOYOTA MEMORIAL HOSPITAL   (Japan)

^p NATIONAL HOSPITAL ORGANIZATION KAGOSHIMA MEDICAL CENTER   (Japan)

^q Ohta Memorial Hospital   (Japan)

^r KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^s KYUSHU UNIVERSITY   (Japan)

more..

Author keywords

Acute stroke care; Anticoagulant; Atrial fibrillation; Cardioembolism; Intracranial hemorrhage; Stroke outcome; Warfarin

Indexed keywords

APIXABAN; DABIGATRAN; HEMOGLOBIN; RIVAROXABAN; WARFARIN; ANTICOAGULANT AGENT;

AGED; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; DISEASE SEVERITY; DRUG EFFECT; EMBOLISM; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROPERITONEAL HEMORRHAGE; RISK BENEFIT ANALYSIS; SUBDURAL HEMATOMA; SYSTEMIC DISEASE; TRANSIENT ISCHEMIC ATTACK; TREATMENT PLANNING; BRAIN ISCHEMIA; CLINICAL TRIAL; COMPLICATION; HOSPITALIZATION; JAPAN; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PROSPECTIVE STUDY; REGISTER; RISK ASSESSMENT; STROKE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; FEMALE; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; JAPAN; MALE; PROSPECTIVE STUDIES; REGISTRIES; RISK ASSESSMENT; STROKE; TREATMENT OUTCOME; WARFARIN;

EID: 84969940524     PISSN: 17474930     EISSN: 17474949     Source Type: Journal    
DOI: 10.1177/1747493016632239     Document Type: Article

References (30)

1. Bogiatzi C, Hackam DG, McLeod AI, et al. Secular trends in ischemic stroke subtypes and stroke risk factors. Stroke 2014; 45: 3208-3213
2. Kato Y, Hayashi T, Tanahashi N, et al. Cardioembolic stroke is the most serious problem in the aging society: Japan standard stroke registry study. J Stroke Cerebrovasc Dis 2015; 24: 811-814
3. Chiang CE, Wang KL and Lip GY. Stroke prevention in atrial fibrillation: an Asian perspective. Thromb Haemost 2014; 111: 789-797
4. Toyoda K, Koga M, Hayakawa M, et al. Acute reperfusion therapy and stroke care in Asia after successful endovascular trials. Stroke 2015; 46: 1474-1481
5. Diener HC, Connolly SJ, Ezekowitz MD, et al. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol 2010; 9: 1157-1163
6. Hankey GJ, Patel MR, Stevens SR, et al. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol 2012; 11: 315-322
7. Easton JD, Lopes RD, Bahit MC, et al. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. Lancet Neurol 2012; 11: 503-511
8. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369: 2093-2104
9. Ntaios G, Papavasileiou V, Diener HC, et al. Nonvitamin-K-antagonist oral anticoagulants in patients with atrial fibrillation and previous stroke or transient ischemic attack: a systematic review and meta-analysis of randomized controlled trials. Stroke 2012; 43: 3298-3304
10. Toyoda K, Arihiro S, Todo K, et al. Trends in oral anticoagulant choice for acute stroke patients with nonvalvular atrial fibrillation in Japan: The SAMURAI-NVAF Study. Int J Stroke 2015; 10: 836-842
11. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285: 2864-2870
12. Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010; 137: 263-272
13. Pisters R, Lane DA, Nieuwlaat R, et al. A novel userfriendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138: 1093-1100
14. JCS Joint Working Group. Guidelines for pharmacotherapy of atrial fibrillation (JCS 2013). Circ J 2014; 78: 1997-2021
15. Hori M, Matsumoto M, Tanahashi N, et al. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation: the J-ROCKET AF study. Circ J 2012; 76: 2104-2111
16. Schulman S and Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3: 692-694
17. Paciaroni M, Agnelli G, Micheli S, et al. Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke: a meta-analysis of randomized controlled trials. Stroke 2007; 38: 423-430
18. Mozaffarian D, Fahimi S, Singh GM, et al. Global burden of Diseases Nutrition and Chronic Diseases Expert Group (NutriCoDE). Global sodium consumption and death from cardiovascular causes. N Engl J Med 2014; 371: 624-634
19. Okata T, Toyoda K, Okamoto A, et al. Anticoagulation intensity of rivaroxaban for stroke patients at a special low dosage in Japan. PLoS One 2014; 9: e113641
20. Kaneko M, Tanigawa T, Hashizume K, et al. Confirmation of model-based dose selection for a Japanese phase III study of rivaroxaban in non-valvular atrial fibrillation patients. Drug Metab Pharmacokinet 2013; 28: 321-331
21. Petty GW, Brown RD Jr, Whisnant JP, et al. Ischemic stroke subtypes: a population-based study of functional outcome, survival, and recurrence. Stroke 2000; 31: 1062-1068
22. Toyoda K, Okada Y and Kobayashi S. Early recurrence of ischemic stroke in Japanese patients: the Japan standard stroke registry study. Cerebrovasc Dis 2007; 24: 289-295
23. Abdul-Rahim AH, Fulton RL, Frank B, et al. Association of improved outcome in acute ischaemic stroke patients with atrial fibrillation who receive early antithrombotic therapy: analysis from VISTA. Eur J Neurol 2015; 22: 1048-1055
24. Paciaroni M, Agnelli G, Falocci N, et al. Early recurrence and cerebral bleeding in patients with acute ischemic stroke and atrial fibrillation: effect of anticoagulation and its timing: The RAF Study. Stroke 2015; 46: 2175-2182
25. Oldgren J, Alings M, Darius H, et al. Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial. Ann Intern Med 2011; 155: 660-667
26. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383: 955-962
27. Fang MC, Singer DE, Chang Y, et al. Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study. Circulation 2005; 112: 1687-1691
28. Sullivan RM, Zhang J, Zamba G, et al. Relation of gender-specific risk of ischemic stroke in patients with atrial fibrillation to differences in warfarin anticoagulation control (from AFFIRM). Am J Cardiol 2012; 110: 1799-1802
29. Pancholy SB, Sharma PS, Pancholy DS, et al. Meta-analysis of gender differences in residual stroke risk and major bleeding in patients with nonvalvular atrial fibrillation treated with oral anticoagulants. Am J Cardiol 2014; 113: 485-490
30. Kinoshita N, Yamagami H, Arihiro S, et al. Abstract TP58: early anticoagulant therapy for secondary stroke prevention in Japanese NVAF patients with TIA/minor stroke: the SAMURAI-NVAF Study. Stroke 2015; 45(Suppl 1): ATP58